Vivani Medical (NASDAQ:VANI - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.
Vivani Medical Stock Performance
Shares of NASDAQ:VANI traded down $0.01 during trading on Wednesday, reaching $1.01. The company had a trading volume of 89,371 shares, compared to its average volume of 174,009. The firm's fifty day moving average is $1.13 and its 200 day moving average is $1.21. The firm has a market capitalization of $59.83 million, a PE ratio of -2.24 and a beta of 3.20. Vivani Medical has a twelve month low of $1.00 and a twelve month high of $2.22.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $4.00 price target on shares of Vivani Medical in a research note on Wednesday, March 26th.
Read Our Latest Research Report on VANI
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Further Reading
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
